Bretazenil
Benzodiazepine, Anxiolytic, Flumazenil, Partial agonist, GABAA receptor, Amnesia, Antidote, Benzodiazepine overdose
978-620-0-21590-1
6200215901
64
2012-01-03
29.00 €
eng
https://images.our-assets.com/cover/230x230/9786200215901.jpg
https://images.our-assets.com/fullcover/230x230/9786200215901.jpg
https://images.our-assets.com/cover/2000x/9786200215901.jpg
https://images.our-assets.com/fullcover/2000x/9786200215901.jpg
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug which is derived from the benzodiazepine family, and was invented in 1988. It is most closely related in structure to the benzodiazepine antagonist flumazenil, although its effects are somewhat different. It is classed as a high-potency benzodiazepine due to its high affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile.
https://morebooks.shop/books/gb/published_by/fer-publishing/189853/products
Medicine
https://morebooks.shop/store/gb/book/bretazenil/isbn/978-620-0-21590-1